Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Northern Africa has been steadily growing in recent years, driven by various factors such as increasing cancer prevalence, rising healthcare expenditure, and growing awareness and accessibility to cancer treatment.
Customer preferences: Patients in Northern Africa are increasingly seeking out more advanced and effective cancer treatments, leading to a growing demand for oncology drugs. Additionally, with the rising middle class in the region, more patients are able to afford expensive cancer treatments.
Trends in the market: Northern Africa has seen a surge in the number of cancer cases, particularly in Egypt and Morocco, which has led to a growing demand for oncology drugs. The market is also witnessing an increase in the number of clinical trials being conducted in the region, indicating a growing interest from global pharmaceutical companies in the Northern African market. Additionally, there has been a shift towards targeted therapy drugs, which are more effective and have fewer side effects than traditional chemotherapy drugs.
Local special circumstances: One of the major challenges faced by the oncology drugs market in Northern Africa is the lack of access to advanced cancer treatments in many parts of the region. This is due to a shortage of healthcare infrastructure and trained medical professionals, as well as the high cost of cancer treatments. However, governments in the region are taking steps to address these issues, such as investing in healthcare infrastructure and partnering with international organizations to improve cancer care.
Underlying macroeconomic factors: The Northern African region is experiencing economic growth, which has led to an increase in healthcare expenditure. Additionally, the region has a large population with a high incidence of cancer, which presents a significant market opportunity for oncology drugs. The region's strategic location also makes it an attractive market for global pharmaceutical companies looking to expand their presence in emerging markets.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
